Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Night Trader who wrote (45398)	11/12/2011 2:43:12 PM
From: Paul Senior	Respond to of 78656

"Biotech shorts are specialists who usually know more than the famous names you mentioned." Well sure. These men making the buy decisions though... I assume they know what they don't know. And since they take in management fees, they would hire biotech analysts and/or appropriate tech consultants to inform them and advise them before they commit funds to these 'esoteric' businesses. So if they do buy, these 'value' investors are betting that they and their biotech long specialists are more right than other biotech specialists who say to avoid or short. --g-- Of course, maybe otoh it's some other professional investors who have hired biotech specialists who have determined that ENZN is a good short candidate who will continue to be proven correct.